{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04838301",
            "orgStudyIdInfo": {
                "id": "Allo-20-001"
            },
            "secondaryIdInfos": [
                {
                    "id": "R01AG063826",
                    "type": "NIH",
                    "link": "https://reporter.nih.gov/quickSearch/R01AG063826"
                }
            ],
            "organization": {
                "fullName": "University of Arizona",
                "class": "OTHER"
            },
            "briefTitle": "Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease",
            "officialTitle": "Safety and Efficacy of Allopregnanolone (Allo) as a Regenerative Therapeutic for Alzheimer's Disease: Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Clinical Trial",
            "acronym": "REGEN-BRAIN\u00a9",
            "therapeuticArea": [
                "Other",
                "Neurology"
            ],
            "study": "allopregnanolone-regenerative-therapeutic-for-mild-alzheimer-s-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-15",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-03-25",
            "studyFirstSubmitQcDate": "2021-04-06",
            "studyFirstPostDateStruct": {
                "date": "2021-04-09",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-30",
            "lastUpdatePostDateStruct": {
                "date": "2023-09-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Roberta Brinton",
                "investigatorTitle": "Director, Center for Innovation in Brain Science; Professor, Departments of Pharmacology and Neurology",
                "investigatorAffiliation": "University of Arizona"
            },
            "leadSponsor": {
                "name": "University of Arizona",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Aging (NIA)",
                    "class": "NIH"
                },
                {
                    "name": "Syneos Health",
                    "class": "OTHER"
                },
                {
                    "name": "ADM Diagnostics, Inc.",
                    "class": "UNKNOWN"
                },
                {
                    "name": "University of Southern California",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.",
            "detailedDescription": "This is a proof-of-concept phase 2 clinical trial to investigate the long-term safety and efficacy of Allo to function as a regenerative therapeutic to restore structural integrity and cognitive function of the brain in participants with mild Alzheimer's disease (AD) dementia. Study participants will be male and female, APOE \u03b54 positive diagnosed with probable AD, Mini-Mental State Exam (MMSE) 20 to 26, ages 55 to 80 years old.\n\nAfter a 2-4-week screening period, participants will be randomized to 4 mg Allo (administered intravenously over 30 minutes, once per week, in clinic) or matching placebo, 1:1 allocation, for a period of 12 months. After 12 months, all participants in the placebo group will be crossed-over to receive Allo for the remainder of the study (6 month open-label phase). Brain imaging to evaluate the primary endpoint will be conducted at baseline, 6 and 12 months."
        },
        "conditionsModule": {
            "conditions": [
                "Alzheimer Dementia",
                "Late Onset Alzheimer Disease",
                "Neurodegenerative Diseases"
            ],
            "keywords": [
                "Mild Alzheimer Disease",
                "Regenerative Therapeutic",
                "APOE \u03b54",
                "Neurogenesis",
                "Allopregnanolone"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "Participants are assigned to the active intervention or placebo in parallel for 12 months. After 12 months, all participants in the placebo group will be crossed-over to receive Allo for the remainder of the study (6 month open-label phase).",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "maskingDescription": "After 12 months participants and study personnel will be aware of the open label phase, but initial randomization will remain blind during the entire length of the study (placebo-controlled and open-label periods); that is, all participants and study personnel are blinded to each participant's randomization to initial treatment group.",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 200,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Allo group",
                    "type": "EXPERIMENTAL",
                    "description": "Allopregnanolone 4mg IV 30-minute infusion once per week for 12 months.",
                    "interventionNames": [
                        "Drug: Allopregnanolone"
                    ]
                },
                {
                    "label": "Control group",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Placebo (normal saline) IV 30-minute infusion once per week for 12 months.",
                    "interventionNames": [
                        "Other: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Allopregnanolone",
                    "description": "Allopregnanolone 4mg IV via 30-minute infusion, once per week.",
                    "armGroupLabels": [
                        "Allo group"
                    ],
                    "otherNames": [
                        "Allo"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "Placebo",
                    "description": "Normal saline solution IV via 30-minute infusion, once per week",
                    "armGroupLabels": [
                        "Control group"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Hippocampal volume",
                    "description": "mm3",
                    "timeFrame": "Baseline to 12 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Cambridge Cognition's Paired Associates Learning Test",
                    "description": "Total errors score (adjusted) - number of errors made by the participant (range: 0 to \\~120). Higher scores indicate poor performance.",
                    "timeFrame": "Baseline to 12 months"
                },
                {
                    "measure": "Cambridge Neuropsychological Test Automated Battery (CANTAB)",
                    "description": "Composite score (higher score indicate better outcome)",
                    "timeFrame": "Baseline to 12 months"
                },
                {
                    "measure": "Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) 11",
                    "description": "Total score (range 0 to 70); higher scores indicate poor performance.",
                    "timeFrame": "Baseline to 12 months"
                },
                {
                    "measure": "Alzheimer's Disease Cooperative Study (ADCS) Instrumental Activities of Daily (iADL) Living (iADL)",
                    "description": "iADL subscore (range 0-56): Lower score indicates greater severity",
                    "timeFrame": "Baseline to 12 months"
                },
                {
                    "measure": "Safety and tolerability",
                    "description": "Frequency of adverse events and serious adverse events",
                    "timeFrame": "Baseline to 12 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Other regional brain volumes",
                    "description": "Change in regional brain volumes (mm3)",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Diffusion tensor imaging (DTI)",
                    "description": "Change in white matter tract diffusion (scalar values and/or mm2/sec)",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Resting state functional MRI",
                    "description": "Change in functional connectivity (z transformed correlations)",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Arterial spin labeling (ASL)",
                    "description": "Change in regional cerebral blood flow (mL/100g)",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Exploratory blood based biomarkers",
                    "description": "Change from baseline in biomarkers of AD pathology, neurogenesis and inflammation",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Clinical Dementia Rating (CDR)",
                    "description": "Sum of boxes score (CDR-SB): range 0-18",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) 14",
                    "description": "Total score (range 0-90)",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Mini Mental State Examination (MMSE)",
                    "description": "Total score (range 0-30)",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Neuropsychiatric Inventory-Questionnaire (NPI-Q)",
                    "description": "Total score (range 0-36). Higher scores indicate greater symptom severity",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "EuroQol 5-Dimension / 5-Level health-related quality of life scale scores (EQ-5D-5L)",
                    "description": "Reported as frequency, percentage and index value.",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Quality of Life in Alzheimer's Disease scale (QoL-AD)",
                    "description": "Total score (range 13-52). Higher score indicate better QoL",
                    "timeFrame": "Baseline to 12 and 18 months"
                },
                {
                    "measure": "Zarit Burden Interview (ZBI)",
                    "description": "Total score (range 0-48). Higher scores indicate high burden",
                    "timeFrame": "Baseline to 12 and 18 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Men and postmenopausal women\n* Age 55 to 80 years old\n* Meets NIA-AA criteria for probable AD dementia\n* MMSE of 20-26\n* APOE \u03b54 positive\n* Geriatric Depression Scale short form (GDS-S) score of \u2264 6\n* No medical contraindications to participation\n* Capacity to provide informed consent at screening\n\nExclusion Criteria:\n\n* Dementia other than probable AD\n* Use of benzodiazepines, anticonvulsants, antipsychotics, or other drugs that might interact with the GABA-A receptor complex\n* History of stroke with a modified Hachinski Ischemic Scale score \\>4\n* History of seizure disorder, focal brain lesion, traumatic brain injury\n* History within the last 5 years of a primary or recurrent malignant disease\n* Unstable or clinically significant cardiovascular, kidney or liver disease\n* MRI indicative of any other significant abnormality, including but not limited to one or more significant ARIA-E or macro-hemorrhage findings, or multiple microhemorrhages (\\>8), or Fazekas score of 3; encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space occupying lesions\n* Any conditions that would contraindicate MRI studies.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "55 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Claudia M Lopez, BS",
                    "role": "CONTACT",
                    "phone": "520-626-6276",
                    "email": "claudiml@arizona.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Roberta D Brinton, PhD",
                    "affiliation": "University of Arizona",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Lon Schneider, MD",
                    "affiliation": "University of Southern California",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Gerson D Hernandez, MD, MPH",
                    "affiliation": "University of Arizona",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Optimus U Corporation",
                    "status": "RECRUITING",
                    "city": "Miami",
                    "state": "Florida",
                    "zip": "33135",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Yaneicy Gonazalez Rojas, MD",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Yaneicy Gonazalez Rojas, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.77427,
                        "lon": -80.19366
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "33344752",
                    "type": "BACKGROUND",
                    "citation": "Hernandez GD, Solinsky CM, Mack WJ, Kono N, Rodgers KE, Wu CY, Mollo AR, Lopez CM, Pawluczyk S, Bauer G, Matthews D, Shi Y, Law M, Rogawski MA, Schneider LS, Brinton RD. Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. Alzheimers Dement (N Y). 2020 Dec 16;6(1):e12107. doi: 10.1002/trc2.12107. eCollection 2020."
                },
                {
                    "pmid": "23438839",
                    "type": "BACKGROUND",
                    "citation": "Brinton RD. Neurosteroids as regenerative agents in the brain: therapeutic implications. Nat Rev Endocrinol. 2013 Apr;9(4):241-50. doi: 10.1038/nrendo.2013.31. Epub 2013 Feb 26."
                },
                {
                    "pmid": "16842093",
                    "type": "BACKGROUND",
                    "citation": "Brinton RD, Wang JM. Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent. Curr Alzheimer Res. 2006 Jul;3(3):185-90. doi: 10.2174/156720506777632817."
                },
                {
                    "pmid": "35310526",
                    "type": "DERIVED",
                    "citation": "Raikes AC, Hernandez GD, Matthews DC, Lukic AS, Law M, Shi Y, Schneider LS, Brinton RD. Exploratory imaging outcomes of a phase 1b/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: Structural effects and functional connectivity outcomes. Alzheimers Dement (N Y). 2022 Mar 14;8(1):e12258. doi: 10.1002/trc2.12258. eCollection 2022. Erratum In: Alzheimers Dement (N Y). 2022 Jul 26;8(1):e12300. doi: 10.1002/trc2.12300."
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000544",
                    "term": "Alzheimer Disease"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                }
            ],
            "ancestors": [
                {
                    "id": "D000003704",
                    "term": "Dementia"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000024801",
                    "term": "Tauopathies"
                },
                {
                    "id": "D000019965",
                    "term": "Neurocognitive Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3885",
                    "name": "Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "asFound": "Neurodegenerative Diseases",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23002",
                    "name": "Tauopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21836",
                    "name": "Neurocognitive Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T2192",
                    "name": "Familial Alzheimer Disease",
                    "asFound": "Alzheimer's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "T312",
                    "name": "Alzheimer Disease Type 2",
                    "asFound": "Late Onset Alzheimer Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3320",
                    "name": "Late-Onset Familial Alzheimer Disease",
                    "asFound": "Late Onset Alzheimer Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011280",
                    "term": "Pregnanolone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000777",
                    "term": "Anesthetics"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M14156",
                    "name": "Pregnanolone",
                    "asFound": "Ad hoc",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4107",
                    "name": "Anesthetics",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                }
            ]
        }
    },
    "hasResults": false
}